Do you want to read an article? Please log in or register.
Establishment and long-term culture of human cystic fibrosis endothelial cells
Related content
RECOMMENDED
Further Publications
Culture of human alveolar epithelial type II cells by sprouting
Respir Res.
Khan P, Fytianos K, Tamò L, Roth M, Tamm M, Geiser T, Gazdhar A, Hostettler KE
doi: 10.1186/s12931-018-0906-9.
Pulmonary Fibrosis
SILDENAFIL IMPROVES VASCULAR ENDOTHELIAL FUNCTION IN PATIENTS WITH CYSTIC FIBROSIS
Am J Physiol Heart Circ Physiol.
Rodriguez Miguelez P, Seigler N, Tucker MA, Csanyi G, McKie KT, Forseen C, Harris RA
doi: 10.1152/ajpheart.00301.2018.
RECOMMENDED
Pulmonary Fibrosis
Predictors of long-term employment among patients with cystic fibrosis undergoing lung transplantation
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Swiss Med Wkly.
Radtke T, Königs A, Chen X, Braun J, Dressel H, Benden C
doi: 10.4414/smw.2020.20286.
RECOMMENDED
Pulmonary Fibrosis
Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry
J Cyst Fibros.
Kaplan S, Lee A, Caine N, Charman SC, Bilton D
doi: 10.1016/j.jcf.2020.08.001.
RECOMMENDED
Further Publications
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE, VX14-661-110 study group.
doi: 10.1016/S2213-2600(20)30510-5
RECOMMENDED
Pulmonary Fibrosis
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Chilvers MA, Davies JC, Milla C, Tian S, Han Z, Cornell AG, Owen CA, Ratjen F
doi: 10.1016/S2213-2600(20)30517-8
RECOMMENDED
Pulmonary Fibrosis
Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros
Kaplan S, Lee A, Caine N, Charman SC, Bilton D
doi: 10.1016/j.jcf.2020.08.001
CoughPulmonary Fibrosis
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Lancet Respir Med.
Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS.
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study
Lancet Respir Med.
Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, Richeldi L
doi: 10.1016/S2213-2600